- Report
- November 2025
- 200 Pages
Global
From €7197EUR$7,950USD£6,177GBP
- Drug Pipelines
- April 2026
- 180 Pages
Global
From €2263EUR$2,500USD£1,942GBP
- Report
- May 2026
- 150 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- May 2026
- 100 Pages
Global
From €2443EUR$2,699USD£2,097GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2525EUR$2,789USD£2,167GBP
- Report
- May 2026
- 150 Pages
Global
From €2443EUR$2,699USD£2,097GBP
- Report
- May 2026
- 150 Pages
Global
From €2443EUR$2,699USD£2,097GBP
- Report
- March 2026
- 200 Pages
Global
From €2525EUR$2,789USD£2,167GBP
- Report
- July 2026
- 200 Pages
Global
From €7233EUR$7,990USD£6,208GBP
- Report
- November 2025
- 150 Pages
Global
From €3395EUR$3,750USD£2,914GBP
- Report
- April 2026
- 142 Pages
Global
From €2715EUR$2,999USD£2,330GBP
€3620EUR$3,999USD£3,107GBP
- Report
- April 2026
- 148 Pages
Global
From €2715EUR$2,999USD£2,330GBP
€3620EUR$3,999USD£3,107GBP
- Report
- August 2026
- 115 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- August 2026
- 130 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- August 2026
- 122 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- July 2026
- 120 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- July 2026
- 130 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- July 2026
- 125 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- July 2026
- 135 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- July 2026
- 135 Pages
Global
From €4300EUR$4,750USD£3,690GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more